neg cells displayed a markedly defective cytotoxicity that could be reversed by blocking the inhibitory receptor CD94/NKG2A. These data open new and important perspectives to better understand the ontogenesis/homeostasis of human natural killer cells and to develop a novel immune-therapeutic approach that targets the inhibitory NKG2A check-point, thus unleashing natural killer cell alloreactivity early after haploidentical hematopoietic stem cell transplantation. BMT pushed the optimization of different haploidentical HSC transplants (hHSCT) that combined different conditioned regimes and immune-modulation therapies. 1 Both myeloablative (MAC) and non-MAC (NMAC) T cellreplete (TCRe) hHSCT followed by post-transplant cyclophosphamide (Cy) gave remarkable positive clinical outcomes. [2] [3] [4] Donor-derived immune-reconstitution (IR) is the most important player ruling out either a positive or negative clinical outcome of allogeneic HSCT. 5 Natural Killer (NK) cells are key for the prognosis of allogeneic BMT given their ability to kill viral-infected or tumor-transformed cells in the absence of a prior sensitization to specific antigens.
6-8 NK cell recognition of "self" relies on a large family of inhibitory NK cell receptors (iNKRs) including killer cell immunoglobulin-like receptors (KIRs) and Ctype lectins, such as CD94/NKG2A, which specifically bind different alleles of major histocompatibility complex of class I (MHC-I). A decreased expression or lack of self-MHC-I on target cells unleash NK cell killing via the engagement of several activating NK cell receptors (aNKRs) (i.e., missing self hypothesis). [9] [10] [11] In the context of allogeneic and non-myeloablative BMT, the presence of a "mismatch" between iNKRs and HLA alleles on recipient cells induces a condition of alloreactivity that makes it possible for donor-derived NK cells to: i) eliminate recipient immune cells that survived the conditioning regimens (i.e., prevent graft reject), ii) kill recipient antigen presenting cells (APCs) presenting host antigens to donor T cells (i.e., avoid the onset of graft-versus-host disease [GvHD]), and iii) clear residual malignant cells in the recipient (i.e., induce graft-versus-leukemia [GvL] effect). These NK cell-mediated effector-functions in mismatched settings are being currently used to develop adoptive NK cell transfer therapies to cure solid and hematologic tumors. 7, 12 Circulating NK cell subsets are normally defined on the basis of CD56 and CD16 surface expression. Conventional CD56 bright /CD16 neg-low (cCD56 bright ) NK cells account for up to 10-15% of the total NK cell population, and are able to secrete a high amount of pro-inflammatory cytokines while displaying poor cytotoxicity. The conventional CD56 dim /CD16 pos (cCD56 dim ) phenotype identifies another highly cytotoxic subset that comprises up to 90% of NK cells in the bloodstream. 13 Other than the pathologic NK subsets expanded in immunological disorders and in response to pathogens, 14 18, 19 The study herein demonstrates that the NK cell IR in TCRe -NMAC-PT/Cy hHSCT with reduced intensity conditioning (RIC) are characterized by the early expansion of donor-derived and anergic uCD56 dim NK cells showing a peculiar NKG2A pos /NKp46 neg-low phenotype. We also demonstrate herein that the blocking of the NKG2A inhibitory pathway on this subset represents an immunotherapeutic target to improve NK cell alloreactivity early after hHSCT.
Methods

Study Design
30 patients were treated according to our published hHSCT protocol approved by the institutional review boards (IRB) of Humanitas Research Hospital. 20 Patients and donors signed consent forms in accordance with the Declaration of Helsinki. Patients' clinical features, enrolment criteria and timing of specimen collections are shown in the Online Supplementary Table  S1 . 21, 22 Peripheral blood mononuclear cells (PBMCs) from healthy volunteers or patients were isolated as previously described. 22, 23 Flow cytometry and cell sorting Cells neg NK cell subsets in peripheral blood (PB) and donor BM by polychromatic flow cytometry on the basis of their CD56 and CD16 surface expression within the lymphocyte gate. 13 We did not include CD56 neg or NKG2D neg lymphocytes in our gating strategy, as these cells were contaminants lacking the NK cell surface markers NKp46, NKG2A, Perforin and Granzyme-B (Online Supplementary Figure S1 ). Our results showed that the absolute numbers of circulating NK cells in hHSCT recipients reach levels similar to those of their healthy donors within four to five weeks after hHSCT with a chimerism that is completely donor-derived after 28 days ( Figure 1A ,B). These findings confirmed that donor-derived NK cells represent the first lymphoid compartment to immune-reconstitute in allogeneic HSCT prior to T and B cells. 6, 7, 21, 22, 24, 25 We then characterized the dynamic of circulating NK cell subset IR early after hHSCT. Four distinct NK cell populations were detectable in both healthy donors and patients and their frequencies were remarkably different within the several time points examined. First, we observed that the frequency of cCD56 bright NK cells was significantly higher in the recipients compared to healthy donors starting from the third week from the transplant, and returned to similar physiologic levels 11 weeks after hHSCT. Conversely, the percentage of the cCD56 dim NK cells was very low, if not undetectable, in the recipients within the same period, and returned similar to that of their related donors five months after the transplant. The 27 To further validate our experimental results performed on cryopreserved cells, we compared the distribution of NK cell subsets between freshly isolated and thawed PBMCs from healthy donors and transplanted patients. Our results showed that both frequencies and phenotypes of the four NK cell subsets from cryopreserved PBMCs are similar to those of freshly purified ones (Online Supplementary Figure S2B- neg /CD20 neg uCD56 dim lymphocytes are indeed NK cells, polychromatic flow cytometry data from 11 healthy donors and from five patients purified three weeks after hHSCT were labelled with a unique computational barcode, concatenated and analyzed by the t-distributed Stochastic Neighbor Embedding (t-SNE) algorithm. 28 We arbitrarily identified 13 different clusters (from C1 to C13) of non-T and non-B lymphocytes on the basis of population boundaries distinguishable on the t-SNE density plots ( Figure 2A ). We then determined the frequency of antigen expression in each cluster by manual gating (Online Supplementary Figure S3) , and displayed the results using a heat map. Figure 2B shows that all clusters except C13 harbor several NK cell surface markers at different degrees of expression. cCD56 bright , cCD56 dim and uCD56 dim NK cell subsets overlap across the distinct clusters defined in the t-SNE map and show a similar distribution in healthy donors and hHSCT recipients ( Figure 2C,D) . cCD56 bright are composed of C7, C8, C9 and, as expected, are NKp46 pos and NKG2A pos while expressing low levels of Granzyme-B and Perforin. cCD56 dim NK cells are present at higher frequencies in healthy donors compared to hHCST recipients and belong to C3, C4, C5, and C6 groups. These cells are characterized by constitutive high expressions of Granzyme-B and Perforin. uCD56 Figure 3A,B) . In line with their previously reported high cytotoxicity, 18 we also observed that uCD56 dim NK cells express high levels of Perforin and Granzyme-B. Interestingly, we also found that uCD56 dim NK cells have low levels of NKp46, thus making this NCR an additional phenotypic marker capable of distinguishing the latter subset from both cCD56 bright and cCD56 dim NK cells ( Figure 3C ).
uCD56 dim NK cells expanded early after hHSCT have a unique transcriptional profile
To gain more insights into the biological and functional relevance of uCD56 dim NK cells, we assessed the gene expression profiles of FACS-sorted circulating NK cell subsets from three healthy donors (three replicates for each of the three cCD56 bright , cCD56 dim and uCD56 dim NK cell subsets) and from their three hHSCT recipients (three replicates for each of the two cCD56 bright and uCD56 dim NK cell subsets) three weeks after the transplant. In order to reduce data dimensionality in three main directions, we first analyzed our results via the principal component analysis (PCA) algorithm. PCA showed that the transcriptional signatures of NK cell subsets from healthy controls are different from those of hHSCT patients ( Figure 4A) 
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after the transplant (Figure 1C,D 
PRF), Granzyme (GRZ-B), GRZ-A and GRZ-H compared to cCD56
bright NK cells from healthy donors ( Figure 4C2 ). Among those transcripts of uCD56 dim NK cells from hHSCT patients similarly expressed in cCD56 bright NK cells from healthy donors (FCx (log 2 ) < |1|) but differently modulated in comparison with cCD56 dim NK cells from healthy donors (FCy (log 2 ) > |1|) we found a downregulation of the maturation marker KLRG1 (Figure 4C 3 ) , of CD160 and GRZ-M (Figure 4C 3 ) .
These transcriptional profiles parallel our flow cytometry data and confirmed our working hypothesis postulating that uCD56 dim NK cells present at high frequencies early after hHSCT are not NK cell precursors, but rather represent lymphocytes in a later stage of differentiation whose gene expression profile is intermediate between cCD56
bright and cCD56 dim NK cells. Figure  5A ). These high rates of NK cell proliferation in hHSCT are associated with the so-called "cytokine storm" which occurs early after allogeneic transplant and induces immune cell activation and differentiation to rapidly recuperate the recipients from the previously induced and lifethreatening condition of immunodeficiency. 25 
Highly proliferating
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NK cells, whose frequencies in the recipient PB increase over the following weeks ( Figure 1C,D) . To validate this working hypothesis, we FACS-sorted uCD56 dim , cCD56 bright and cCD56 dim NK cells from healthy donors ( Figure 5B ), cultured them with IL-15 plus IL-18 and analyzed the phenotype of proliferating cells diluting carboxyfluorescein succinimidyl ester (CFSE) at several time points. IL-15 was chosen on the basis of its enhanced ability to prime NK cell proliferation and because it is increased significantly in the blood of the recipient receiving allogeneic (including haploidentical) HSCT. 25, 31, 32 Similarly, IL-18 is known to have a deep impact on NK cell activation and effector-functions. 33, 34 In this regard, our transcriptional data showed that IL-18 receptor-1 (IL-18-R1) is significantly upregulated in uCD56 dim NK cells from hHSCT patients compared to cCD56 dim NK cells from healthy donors (FCy (log 2 ) > |1|) (Online Supplementary  Table S4 ). In line with our transcriptional data (Figure 4) Figure 5D and Figure 6 ).
uCD56
dim cells expanded early after hHSCT are anergic due to high expression of NKG2A
Our phenotypic analyses showed that donor-derived uCD56 dim NK cells expanded early after hHSCT patients are fully armed to efficiently kill tumor cell targets, as already demonstrated in healthy donors.
18 Surprisingly, 
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we found the degree of CD107a degranulation against K562 cell line of uCD56 dim cells purified from hHSCT recipients after six weeks from transplant is significantly lower compared to that of their counterparts from healthy donors ( Figure 7A,B) .
Considering that the cytolytic activity of NK cells is licensed by the dominant regulation of iNKRs over aNKRs, 10, 11 we screened the expression of a large panel of inhibitory receptors, over time, that could likely explain the anergy of donor-derived uCD56 dim NK cells from
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1398 haematologica | 2018; 103(8) dim NK cells in the PB of recipients compared to their related healthy donors is detectable between the fourth and eleventh week following hHSCT ( Figure 7C ).
To understand if this high and transient expression of CD94/NKG2A on donor-derived uCD56 dim NK cells reconstituting the recipients could explain their defective cytotoxicity, we performed masking experiments by blocking this iNKR in the presence of a tumor cell line expressing its putative ligand HLA-E (i.e., 721-221G cell line). 35, 36 Both cCD56 bright and uCD56 dim NK cells from healthy donors are able to efficiently degranulate, and the masking with an anti-CD94/NKG2A mAb increased the expression of CD107a only in cCD56 bright , in line with their high constitutive expression of NKG2A. In contrast, both cCD56 bright and uCD56 dim NK cells purified from hHSCT after six weeks from the transplant are not able to efficiently degranulate against 721-221G, and only the blocking of the CD94/NKG2A inhibitory checkpoint significantly increases the expression of CD107a of these NK cell subsets ( Figure 7D ).
Discussion
The recent development of TCRe-NMAC-PT/Cy hHSCT with RIC represented a revolution in the field of BMT for the cure of hematologic malignancies. 1, 2, 37 The study herein characterizes the transient and early expansion of a functionally exhausted subset of donor-derived uCD56 dim NK cells that is detectable at a high frequency from the second week after the transplant. uCD56 dim NK cells are by far the largest NK cell population in the first weeks after hHSCT and are also characterized by a significant higher expression of CD94/NKG2A compared to their counterparts in healthy donors. The increased surface levels of this iNKR early after hHSCT greatly impairs the cytotoxicity of uCD56 dim NK cells, thus affecting those 25 The first NK cell subsets to be detected starting from the second week after hHSCT are the cCD56 bright and uCD56 dim NK cells, with the latter population being by far the largest one, expanded early in the first weeks after the transplant. cCD56 bright and uCD56 dim cells are not NK cell precursors and are able to exert a bi-directional differentiation following stimulation with IL-15, a pro-inflammatory cytokine present at high levels in the sera of lymphopenic recipients in the first weeks after allogeneic transplant. 25, 31 (B) Clinical impact (lower right): due to the high constitute expression of the inhibitory receptor NKG2A, uCD56dim NK cells are exhausted in their cytolic potential, and this impairment greatly affects: i) the clearance of residual malignant cells in the recipient that survived the conditioning regimens (i.e., decreased graft-versus-leukemia (GvL) effect), ii) the killing of recipient antigen presenting cells (APCs) presenting host antigens to donor T cells (i.e., increase in the onset of graft-versus-host disease [GvHD]), and iii) the elimination of recipient immune T cells that survived the conditioning regimens (i.e., decrease in engraftment). 7 (C) Therapeutic insights (upper right): the blocking of the NKG2A inhibitory checkpoint unleashes donor-derived NK cell cytotoxicity and increases their alloreactive potential. Hence, the PT infusion of the humanized anti-NKG2A monoclonal antibody (i.e., Monalizumab) represents a potential novel therapeutic approach to improve the clinical outcome of hHSCT. neg NK cells reconstituting in the recipients derive from donor HSCs. 25 Nonetheless, the kinetic and the clinical impact of NK cell subset distribution in this transplant setting are unknown. Even though the absolute numbers of donor-derived NK cells are restored in the recipients few weeks after the transplant, we show herein that the distribution of their subset takes much longer to acquire a pattern similar to that observed in healthy donors. 13 In particular, hHSCT recipients either lack, or have very low frequencies, of circulating cCD56 dim NK cells soon after the transplant. The lack of the main cytolytic population that normally accounts for up to 90% of all circulating NK cells is compensated by the expansion, starting from the second week after hHSCT of uCD56 dim NK cells, that appear before cCD56 dim NK cells and that are present at a higher frequency compared to cCD56 bright NK cells early after the transplant. These findings prompted us to first hypothesize that uCD56 dim NK cells might represent an additional stage of NK cell differentiation preceding the appearance of cCD56 bright and cCD56 dim cell subsets. By focusing our analyses on the different transcriptional profiles of NK cell subsets from healthy donors, we first highlighted the peculiar signature of the uCD56 dim NK cell subset. These data made it possible to understand how recipients are repopulated over time by specific subsets of donorderived NK cells that are affected by the peculiar lymphopenic environment early after hHSCT, and follow a kinetic highly impacting the functional outcome of the transplant. Indeed, both our transcriptional profiles and phenotypic analyses in healthy donors and hHSCT recipients showed that uCD56 dim lymphocytes are bona fide NK cells and not NK cell precursors, are not an artifact of cryopreservation, and express surface markers of late differentiation such as NKG2D and NKp30 as well as lytic granules indicative of a cytotoxic phenotype. Our results are in line with previous studies showing that uCD56 dim NK cells in healthy donors, although present at a very low frequency, represent a distinct subset able to efficiently kill tumor cell targets. [15] [16] [17] It has also been reported that the lack or decreased expression of CD16 on activated and degranulating cCD56 dim NK cells is mediated by the metalloproteinase-17 (ADAM17), thus potentially explaining, at least in part, the origin of uCD56 dim NK cells. 38, 39 Considering that mature and highly proliferating NK cells infused with the graft do not survive to the PT/Cy, 25 it is highly unlikely that the action of ADAM17 on activated cCD56 dim NK cells could alone explain the high frequencies of uCD56 dim NK cells early after hHSCT. Indeed, the expansion of this latter circulating NK cell subset has its peak in the first weeks after hHSCT, when cCD56 dim NK cells are either undetectable or present at very low frequencies ( Figure  1C,D) . Moreover, uCD56 dim NK cells are characterized by a remarkably high degree of cellular proliferation in response to cytokine activation, are able to generate cCD56 bright NK cells, and express a NKp46 neg-low phenotype. These functional and phenotypic features do not belong to terminally differentiated cCD56 dim NK cells and are neither induced nor mediated by mechanisms associated with ADAM17 cleavage properties. As a matter of fact, we did not find any difference in the transcriptional levels of ADAM17 between cCD56 dim and uCD56 dim NK cells purified early after hHSCT (data not shown). Taken together, these data indicate that ADAM17 likely plays a minor role, if any, in the expansion of uCD56 dim NK cells early in hHSCT.
In the context of the cytokine storm characterizing the systemic lymphopenic environment early after allogeneic HSCT (including hHSCT), IL-15 certainly plays a key role as it is highly increased in patients' sera in the first week after the transplant. 25 bright NK cells in an ex vivo human setting mimicking a lymphopenic environment highly enriched with IL-15. We are certainly aware that this methodological approach does not resemble the complex cellular and molecular interactions occurring in the human BM niche during lymphopoiesis. Indeed, neither uCD56 dim nor cCD56 bright NK cells were able to generate terminally-differentiated cCD56 dim NK cells, a process that requires the presence of additional signals delivered by fibroblasts, mesenchymal and stromal cells. [40] [41] [42] However, herein we clearly show that both proliferating uCD56 dim and cCD56 bright NK cells can generate either themselves or their "neighbor" NK cell subset. In this context, the high serum level of IL-15 soon after hHSCT 25 could also be manipulated to boost a more potent antitumor response by cCD56 bright NK cells, as recently demonstrated in multiple myeloma. 43 Further studies are needed in order to disclose the mechanisms that finely tune the bi-directional transition between uCD56 dim and cCD56 bright , both under physiologic conditions and in the lymphopenic setting following allogeneic HSCTs.
Herein, we also demonstrate that the transcriptional profile of uCD56 dim NK cells expanded early after hHSCT is distinct from that of their counterparts in healthy donors. This is not surprising in the context of an allogeneic transplant where different stimuli, such as lymphopenia, alloreactivity, a high serum level of cytokines, antigen stimulation, opportunistic viral infections and acute GvHD highly influences the quantity and the quality of IR. 1, 24, 25 Indeed, this peculiar systemic environment induces the preferential expansion starting from the second week after hHSCT of uCD56 dim NK cells which, although showing a cytotoxic phenotype, are highly defective in the clearance of tumor cell targets. This cellular functional exhaustion is associated, at least in part, with the transient expression of CD94/NKG2A on all uCD56 dim NK cells that account for the majority of the NK cell population within the first weeks following trans-plant. Indeed, the blocking of CD94/NKG2A with a masking mAb significantly increased the CD107a degranulation as a marker of lytic activity of NK cells purified early after hHSCT. Although the mechanism(s) inducing the expansion of anergic NKG2A pos /uCD56 dim NK cells is unknown, this acquired knowledge now makes it possible to develop a therapeutic approach targeting a specific immune check-point whose inhibition can efficiently increase NK cell alloreactivity within a given time-frame after hHSCT. In this regard, the efficacy of the in vivo administration of an anti-CD94/NKG2A blocking mAb (i.e., Monalizumab) in improving NK cell cytotoxicity against solid tumors and leukemic cells has been already reported both in mice and humans. 44, 45 (clinicaltrials.gov Identifier: 02459301) (Figure 8 ).
